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Background: Investigational approaches based on genome-wide association studies have proven useful
in identifying genetic predictors for many diseases, including susceptibility to chronic hepatitis B and C.
In these studies, the majority of genetic variants that have shown a positive association have been
identiﬁed in genes involved in the immune response. In this study IFN-g, IFNGR-1, and IRF-1 genes were
analyzed for their role in susceptibility to the development of chronic hepatitis B and chronic hepatitis C
in a Turkish population.
Methods: Polymorphic genes IRF-1 (410, 388), IFNGR-1 (56, 611), and IFN-g (+874) were analyzed
in a total of 400 individuals: 100 chronic hepatitis B patients, 100 hepatitis B carriers, 100 chronic
hepatitis C patients, and 100 healthy controls. A single base primer extension assay was used.
Correlations between genes and gender, viral load, and aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels were also investigated.
Results: The IRF-1 gene at positions 388 and 410 were observed to be candidate gene markers for
susceptibility to the development of chronic hepatitis B and C (p < 0.05). IFN-g +874 and IFNGR-1 (56
and 611) correlated with chronic hepatitis B but not chronic hepatitis C. Correlation of functional
genotype with viral load and AST and ALT levels revealed an association of IFN-g +874 and IFNGR-1 611
with chronic hepatitis C and IFN-g +874 with viral load and chronic hepatitis B (p < 0.05).
Conclusions: Findings suggest that IFN-g (+874), IRF-1 (410, 388), and IFNGR-1 (56, 611) are
candidate gene markers for determining patient susceptibility to the development of chronic hepatitis B
and C.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Upon invasion of hepatocytes with the hepatitis B virus (HBV)
or hepatitis C virus (HCV), a host defense-mediated response is
triggered, which involves the induction of the interferon family of
pleiotropic cytokines.1 Interferons constitute a heterogeneous
group of proteins and are best known for their ability to induce
cellular resistance to viral infections. Interferon gamma (IFN-g) is
the only type II interferon and is a markedly different cytokine to
the type I interferons. Its classiﬁcation into the interferon family is
due to its role in host antiviral mechanisms.2* Corresponding author. Tel.: +90 216 578 2653; fax: +90 216 578 0829.
E-mail address: mkorachi@yeditepe.edu.tr (M. Korachi).
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other cell types, including natural killer cells, CD8 T cells, and
macrophages. It acts as a regulator of gene expression through
activation of a receptor complex comprising two subunits, each
encoded by a different gene: IFN-g receptor IFNGR-1 on chromo-
some 6q23–4 and IFNGR-2 on chromosome 21q22.1–22.2. Homo-
dimers of IFN-g interact with both receptor proteins leading to
receptor dimerization, and each of the three molecules plays a non-
redundant role in ligand-activated receptor signaling.3,4
The intracellular antiviral responses induced by IFN-g play a
critical role in the pathogenesis of HBV and HCV infection.1 Upon
induction of the signaling pathway, IFN-g functions in an
autocrine manner to up-regulate the transcription factor inter-
feron regulatory factor 1 (IRF-1) and its target genes.5,6
Subsequently, a feedback loop in which IFN-g and IRF-1 are up-
regulated results in the ampliﬁcation of the IFN-g-dependentses. Published by Elsevier Ltd. All rights reserved.
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for the clearance of HBV is well known.1,7 It has been shown that
IFN-g can inhibit the replication of HBV-infected cells, directly
reducing viral load by mediating the antiviral effect of the
cytotoxic lymphocytes (CTLs).8
These cellular responses mediated by interferon are primarily
due to the modulation of gene expression, which in turn can be
modulated by certain gene polymorphisms. Genetic polymor-
phisms of these cytokines and their receptors can occur in multiple
allelic states. The presence/absence of certain polymorphisms has
been shown to affect the expression and the production of various
cytokines, both in vitro and in vivo,9 thereby playing a role in
susceptibility to a number of clinical conditions, such as
autoimmune diseases, infectious diseases, and graft rejection.9
Several polymorphisms within the IFN-g non-coding regions have
been implicated in autoimmune, chronic inﬂammatory condi-
tions10 and HBV infection.11 Furthermore, cytokine polymor-
phisms involved in the IFN-g signaling pathway have previously
been found to play a role in other viral/host-mediated immune
responses, including IFNGR-1, which has been shown as a strong
candidate gene for the complex phenotype of tuberculosis,12 while
polymorphisms in the IRF-1 region have been linked to altered
susceptibility to numerous infections and immunopathologies
including schistosomiasis and allergy/atopy.13–15 IRFs are known
to be important for the initiation and ﬁne-tuning of immune
responses. They comprise a tight regulatory network of genes that
have shown importance in promoting antibacterial immunity.16,17
Previous studies have suggested that human hepatoma cell lines
show different levels of IRF-1 transcription in response to
interferons, thereby affecting the regulation of hepatic inﬂamma-
tion and viral eradication by interferon treatment for chronic viral
hepatitis.18
This study investigated whether genetic variation(s) in
cytokines and receptors (IFN-g, IFNGR-1, and IRF-1) involved in
the interferon type II pathway, are associated with susceptibility to
the development of chronic HBV and HCV infections in a Turkish
population. Allele and genotype distributions were compared
between chronic hepatitis B (CHBV) and chronic hepatitis C (CHCV)
subjects, asymptomatic hepatitis B carriers, and healthy controls.
Furthermore, correlations between polymorphisms in these genes
were analyzed with respect to gender distribution, viral load, and
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) levels. Any association with these genes will provide insight
into the clinically important immune mechanisms inﬂuencing
these infectious diseases.
2. Materials and methods
2.1. Study subjects
This was a case–control study including a total of 400 Turkish
adults (205 males and 195 females). Subjects were enrolled from
the outpatient clinics of the gastroenterology departments of
Haydarpas¸ a Numune Teaching Hospital and Umraniye Teaching
and Research Hospital in Istanbul, Turkey, between March 2009
and May 2011.
Patients were classiﬁed into the following groups: (1) Chronic
HBV infection: 100 individuals (mean  SD age, 52.74  13.17
years) who were hepatitis B surface antigen (HBsAg)-positive,
antibody to hepatitis B core antigen (anti-HBc) IgG-positive, antibody
to hepatitis B e antigen (anti-HBe)-positive, had an HBV-DNA level
>2000 IU/ml,19 without anti-HCV antibodies, manifested by elevated
ALT (more than two times the upper limit of normal) during the
follow-up period of 6 months. (2) HBV carriers: 100 individuals
(mean  SD age, 43.26  11.42 years) who were considered inactive
HBsAg carriers based on a sustained normal ALT level, with positivityfor anti-HBe and an undetectable level of HBV-DNA; (3) Chronic HCV
infection: 100 individuals (mean  SD age, 44.13  12.11 years) who
were positive for HCV antibodies but negative for HBV antigens, and
had an HCV-RNA level >800 000 IU/ml and ALT values more than
two times the upper limit of normal. (4) Healthy controls: 100
individuals (mean  SD age, 46.32  11.29 years) who were nega-
tive for HBV and HCV, with normal liver transaminase levels and
ultrasonography.
All subjects were regularly followed with blood tests for serum
transaminase and with ultrasonography at 6-month intervals for
more than 18 months. No patients were diagnosed with
hepatocellular carcinoma. Patients with other types of chronic
liver disease were excluded from the study. Informed consent was
obtained from each patient included in this study and the study
protocol conformed to the ethics guidelines of the 1975 Declara-
tion of Helsinki, as reﬂected in the prior approval of the
institutional human research committees.
2.2. Determination of AST and ALT levels
Plasma ALT and AST activity was routinely evaluated by spec-
trophotometric method, in 100 ml of plasma.20 Following a 10-min
incubation at room temperature, the absorbance was measured
at l = 340 nm by spectrophotometer (Thermoscientiﬁc, UK).
2.3. HBV DNA and HCV RNA quantiﬁcation
HBV and HCV serologic markers were tested using commer-
cially available enzyme immunoassays (Abbott Laboratories,
Chicago, IL, USA). HBV and HCV nucleic acids were extracted from
blood using Trizol-LS (Life Technologies, Paisley, UK), or by Roche
DNA/RNA extraction kit (Roche, Germany), and were resuspended
in nuclease-free water (Promega, Madison, WI, USA). HBV-DNA
and HCV-RNA were ampliﬁed using Cobas Taqman kits, as per the
manufacturer’s instructions (Roche, Germany), and was quantiﬁed
using a Roche Cobas Taqman 48 Analyzer with a lower detection
limit of 25 IU/ml in serum.
All samples were analyzed in duplicate and the mean value
reported as the viremic level in the serum.
2.4. Single nucleotide polymorphism genotyping
Genomic DNA was extracted from 200 ml of a peripheral whole
blood sample using a commercially available DNA isolation kit
(Qiagen, UK) in accordance with the manufacturer’s instructions.
Five single nucleotide polymorphisms (SNPs) of three polymorphic
genes were assessed in all study subjects: IRF-1 gene promoter
positions 410 and 388, IFN-g gene at position +874, and IFNGR-1
at 56 and 611. The sequences of the primers and probes used in
the PCR assays are shown in Table 1; the sequencing primers were
designed from the National Center for Biotechnology Information
(NCBI) sequence data.21
PCR products were puriﬁed by a Qiagen PCR puriﬁcation kit, and
the polymorphisms detected by single base primer extension assay
(SNP-IT assay) using a previously described method.22 The
thermocycling parameters for interferon genes were as follows:
an initial activation step of 95 8C for 10 min preceded the cycling
program, followed by 35 cycles of denaturation at 95 8C, annealing
at 72 8C for 1 min, and ﬁnal extension at 72 8C for 7 min.
2.5. Statistical analysis
Results were analyzed using SPSS version 11.0 software (SPSS,
Inc., Chicago, IL, USA). The Hardy–Weinberg equilibrium (HWE) of
the polymorphic frequency for alleles and genotypes were
compared by Chi-square test. An independent sample t-test was
Table 1
Sequences of PCR amplifying primers and extension primers
IRF-1 (410) 50-agtgttcccactggagagg-30
50-atcttttcaccctcctggc-30
Extension primer: cggcaagtgcccgggcgatcccctc
G!A
IRF-1 (388) 50-agtgttcccactggagagg-30
50-ctcctggggccatctttt-30
Extension primer: ccctcacctgcgttcxggagatatacc
T!C
IFN-g (+874) 50-atattcagacattcacaattgatt-30
50-tattattatacgagctltaaaagatagttcc-30
Extension primer: 50-cgagcgcctgcgggaccagcccagc-30
T!A
IFNGR-1 (611) 50-acgttggatgcttctcagcaattcagtgtc-30
50-acgttggatgcaaacccagagaggtaagag-30
Extension primer: 50-ttcagtgtcaaatcagtttat-30
G!A
IFNGR-1 (56) 50-acgttggatgagagccatgctgctaccgac-30
50-acgttggatgtgacggaagtgacgtaaggc-30
Extension primer: 50-tgcgggaccagcccagc-30
T!C
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loads. Fisher’s exact test was used for testing the independence of
categorical variables. All p-values were two-tailed, and a p-value of
<0.05 was considered to indicate statistical signiﬁcance through-
out the study. Odds ratios (ORs) with 95% conﬁdence intervals
(95% CI) were computed by logistic regression.
3. Results
Distribution of allele and genotype frequencies in IRF-1 (410,
388), IFN-g (+874), and IFNGR-1 (611, 56) were investigated
for CHBV patients, HBV carriers, CHCV patients, and healthy
controls. Table 2 summarizes the data regarding the frequency
distribution in the four subject groups.
3.1. Hepatitis B
Comparison of the frequency distribution of the different
dimorphic polymorphisms in the CHBV and HBV carrier groups
revealed the presence of the A allele (p = 0.001; OR 2.88, 95% CI
1.5–5.5) and AA genotype (p = 0.04; OR 2.86, 95% CI 1.0–8.0) of
IRF-1 at position 410 to be predominant in CHBV patients.
Conversely, heterozygous genotype AG was seen to be more
prevalent in HBV carriers (70%) (p = 0.025; OR 0.35, 95% CI
0.14–0.9). No other genes were observed as discriminatory between
CHBV and HBV carriers (p > 0.05).
Further analysis of the IRF-1 (410) gene in the HBV carrier and
healthy control groups, revealed signiﬁcant distributions of the AG
(p = 0.00; OR 0.21, 95% CI 0.1–0.5) and AA (p = 0.001; OR 4.66, 95%
CI 1.78–12.3) genotypes correlating to asymptomatic carriers and
healthy subjects, respectively. While no signiﬁcant association of
this promoter polymorphism was seen with regards to CHBV vs.
healthy controls (p > 0.05), the frequency distribution of the study
groups at the IRF-1 388 position revealed the TC genotype to be
signiﬁcantly higher in chronic patients than in carriers and controls
(p < 0.05).
Analysis of CHBV with healthy controls against other test genes
revealed a marked signiﬁcance in the IFN-g (+874) and IFNGR-1
(611 and 56) genes. There was a strong association of the IFN-g
(+874) AA genotype with CHBV (p = 0.001; OR 0.31, 95% CI 0.15–
0.60) and IFN-g (+874) TT with healthy controls (p = 0.000; OR
6.85, 95% CI 1.9–23.46). No allelic signiﬁcance was demonstrated
in the IFNGR-1 gene, however the AA and CC genotypes (at
positions 611 and 56, respectively), showed higher frequency
distributions in healthy subjects than in disease groups (CHBV vs.
healthy controls: AA, p = 0.004; CC, p = 0.006; HBV carriers vs.
healthy controls: AA, p = 0.005; CC, genotype absent). Heterozy-
gous genotypes at these same respective positions were signiﬁ-
cantly related to the presence of HBV infection (CHBV vs. healthycontrols: AG, p = 0.003; CT, p = 0.001; HBV carriers vs. healthy
controls: AG, p = 0.005; CT, p = 0.001).
3.2. Hepatitis C
Comparative analysis of the IRF-1 gene with CHCV vs. healthy
control subjects revealed the AA (p = 0.000; OR 10.5, 95% CI 3.5–
31.4) and AG genotypes (p = 0.00; OR 0.19, 95% CI 0.08–0.42) at
position 410 and TC (p = 0.01; OR 0.22, 95% CI 0.06–0.78) at the
388 site to be associated with the development of chronic
hepatitis. Furthermore, it was observed that the IFN-g and
IFNGR-1 genes did not play a signiﬁcant role in susceptibility to
CHCV.
3.3. Chronic hepatitis B vs. chronic hepatitis C
Further statistical analyses of the studied polymorphic genes
were performed between the two chronic disease groups (CHCV vs.
CHBV), in order to observe any similar associations and hence
possible roles in the development of chronic hepatitis. The allelic
distribution G/A of the IRF-1 (410) gene, revealed a signiﬁcance
(p = 0.017; OR 2.29, 95% CI 1.15–4.54) with the A allele (64%) in
CHBV patients. The AA (p = 0.036; OR 8.41, 95% CI 1.0–70.6) and AG
(p = 0.031; OR 0.26, 95% CI 0.07–0.8) genotypes of IFNGR-1 (611)
were also observed to play a signiﬁcant role in susceptibility to
CHCV and CHBV, respectively.
3.4. Genotype vs. gender, viral load, and AST and ALT levels
Clinical and demographic characteristics of the CHBV and CHCV
groups were further compared with genotypes on the basis of
gender, viral load, and AST and ALT levels (Table 3). No statistical
signiﬁcance was observed for either patient group with respect to
gender (p > 0.05).
Signiﬁcant frequency distributions of IFN-g (+874) AA and AT
genotypes were observed in CHBV patients with viral loads
>2000 IU/ml (p = 0.041 and p = 0.046, respectively), while the
IRF-1 (410) GG (p = 0.017) and IFNGR-1 (611) AA (p = 0.033)
were prevalent in CHCV subjects with high viral loads. Although the
statistical analysis revealed no association with any of the studied
genes with regards to CHBV and AST/ALT levels, the IFNGR-1 (611)
AA genotype was signiﬁcantly associated with elevated AST
(p = 0.015) and ALT (p = 0.016) levels in CHCV patients.
4. Discussion
Based on the known importance of the IFN-g pathway in the
host immune response to viral infections and the critical role of IRF
and IFNGR-1 in IFN-g signaling, we inferred that genetic variations
in these genes may have an impact on the development of HBV
and/or HCV chronic infections.
The ﬁndings demonstrated the IRF-1 gene at positions 410 and
388 to be markers for predicting susceptibility to the develop-
ment of CHBV. IRF-1 388 appeared to be a signiﬁcant
discriminating factor between health and the chronic form of
the disease. These ﬁndings conﬂict with the results of Cheong
et al.,23 who found no association for the IRF-1 gene at these
positions in HBV-infected patients in a Korean population.
Differences could be due to the different study cohort and ethnic
population.
The IRF-1 gene at the 388 (T/C) position was also seen to
determine the development of CHCV. Although no investigation of
the IRF-1 gene at positions 410 and 388 in HCV has been
documented, IRF-1 (300) AA genotype has been related to the
outcome and therapeutic response to HCV infection, in which a
lower IRF-1 expression and reduced IRF-1 responsiveness are
Table 2
Distribution and statistical analysis of allele and genotype frequencies in chronic hepatitis B and chronic hepatitis C patients, hepatitis B carriers, and healthy controls
Gene,
allele/genotype
CHBV
% (A)
HBVc
% (B)
CHCV
% (C)
Healthy
controls
% (D)
p-Valuea
(A,B)
OR
(95% CI)
(A,B)
p-Valuea
(A,D)
OR
(95% CI)
(A,D)
p-Valuea (B,D) OR
(95% CI)
(B,D)
p-Valuea
(C,D)
OR
(95% CI)
(C,D)
p-Valuea
(A,C)
OR
(95% CI)
(A,C)
IRF-1 (410) G 36 62 41 30 0.001b 2.88b (1.5–5.5) 0.224 1.34 (0.84–2.13) 0.001b 3.84 (2.13– 6.95) 0.052 1.67 (0.99–2.84) 0.017b 2.29 (1.15–4.54)
A 64 38 59 30
GG 13 10 13 13 0.746 1.38 (0.3–5.6) 0.923 0.96 (0.38–2.4) 1.000 1.32 (0.36–4.91) 0.958 0.69 (0.26–1.85) 0.498 1.90 (0.45–8.10)
AG 45 70 75 33 0.025b 0.35b (0.14–0.9) 0.129 0.61 (0.32– 1.2) 0.000b 0.21 (0.1–0.51) 0.000b 0.19b (0.08–0.42) 0.819 1.13 (0.39–3.21)
AA 42 20 12 54 0.040b 2.86b (1.0–8.0) 0.125 1.63 (0.87–3.06) 0.001b 4.66 (1.78–12.3) 0.000b 10.5b (3.5–31.4) 0.308 0.44 (0.11–1.74)
IRF-1 (388) T 48 55 49 46 0.343 1.35 (0.73–2.5) 0.810 1.06 (0.7–1.6) 0.221 1.43 (0.81–2.52) 0.688 1.11 (0.66–1.84) 0.464 1.28 (0.65–2.51)
C 53 45 51 54
TT 3 13 2 9 0.093 0.22 (0.04–1.3) 0.224 3.01 (0.65– 14.0) 0.509 0.67 (0.2–2.29) 0.298 4.04 (0.51–32.4) 0.157 0.17 (0.02–1.58)
TC 88 83 93 74 0.511 1.5 (0.44–5.25) 0.023b 0.36b (0.15–0.9) 0.344 0.55 (0.19–1.57) 0.013b 0.22 (0.06–0.78) 0.275 2.47 (0.54–11.7)
CC 8 3 5 17 0.659 2.6 (0.29–23.6) 0.113 2.27 (0.80–6.38) 0.077 5.98 (0.77–46.5) 0.067 3.92 (0.87–17.5) 1.000 1.53 (0.13–17.6)
IFN-g (+874) A 67 62 45 44 0.507 0.80 (0.42–1.5) 0.000b 2.50b (1.58–3.96) 0.017b 2.01 (1.12–3.59) 0.931 1.02 (0.61–1.70) 0.051 1.96 (0.99–3.88)
T 33 38 55 56
AA 38 27 20 16 0.272 1.71 (0.65–4.5) 0.001b 0.31b (0.15–0.6) 0.188 0.53 (0.21–1.37) 0.586 0.77 (0.31–1.94) 0.511 0.68 (0.22–2.11)
AT 57 63 50 56 0.545 0.76 (0.31–1.9) 0.974 0.99 (0.53–1.8) 0.493 0.74 (0.33–1.71) 0.482 1.29 (0.63–2.66) 0.266 0.57 (0.22–1.52)
TT 5 10 30 27 0.396 0.47 (0.9–2.5) 0.000b 6.85b (1.9–23.46) 0.087 3.24 (0.92–11.5) 0.668 0.84 (0.38–1.85) 0.075 3.85 (0.98–15.2)
IFNGR-1 (611) A 49 47 54 56 0.752 0.91 (0.49–1.7) 0.196 0.74 (0.48–1.2) 0.176 0.67 (0.38–1.2) 0.679 0.89 (0.53–1.49) 0.407 0.75 (0.38–1.47)
G 51 53 46 44
AA 8 3 23 27 0.659 2.64 (0.3–23.6) 0.004b 3.96b (1.4–10.8) 0.005b 10.45 (1.4– 80.0) 0.617 1.24 (0.53–2.89) 0.036b 8.41 (1.0–70.6)
AG 82 87 63 60 0.765 0.68 (0.2–2.4) 0.003b 0.33b (0.15–0.7) 0.005b 0.22 (0.07–0.69) 0.765 0.89 (0.42–1.87) 0.031b 0.26 (0.07–0.8)
GG 10 10 14 14 1.000 1.0 (0.23–4.31) 0.632 1.43 (0.53–3.85) 0.765 1.43 (0.38– 5.2) 0.835 0.89 (0.32–2.48) 0.723 1.58 (0.36–6.9)
IFNGR-1 (56)
C 50 47 50 55 0.673 0.87 (0.5–1.63) 0.401 0.83 (0.53/1.28) 0.266 0.73 (0.41–1.3) 0.467 0.82 (0.49–1.37) 0.696 0.87 (0.44–1.71)
T 50 53 50 45
CC 7 0 10 23 -c -c 0.006b 4.20b (1.4–12.6) -c -c 0.106 3.92 (0.87–17.5) 1.000 1.53 (0.13–17.6)
CT 87 93 80 63 0.486 0.46 (0.09–2.3) 0.001b 0.26b (0.12–0.6) 0.001b 0.12 (0.03–0.5) 0.051 0.43 (0.18–1.02) 0.171 0.28 (0.06–1.5)
TT 5 7 10 14 1.000 0.74 (0.12–4.6) 0.122 3.01 (0.84–10.8) 0.369 2.21 (0.48–10.2) 0.784 1.42 (0.45–4.54) 0.694 1.55 (0.26–9.1)
CHBV, chronic hepatitis B; HBVc, hepatitis B carriers; CHCV, chronic hepatitis C; OR, odds ratio; CI, conﬁdence interval.
a p-Value calculated using the Pearson Chi-square test; p<0.05 indicates signiﬁcance.
b Signiﬁcant.
c Could not be calculated because of the absence of CC genotype.
M
.
 K
o
ra
ch
i
 et
 a
l.
 /
 In
tern
a
tio
n
a
l
 Jo
u
rn
a
l
 o
f
 In
fectio
u
s
 D
isea
ses
 1
7
 (2
0
1
3
)
 e4
4
–
e4
9
 
e4
7
Table 3
Genotype distribution analysis of chronic hepatitis B and chronic hepatitis C with viral load, aspartate aminotransferase and alanine aminotransferase levels, and gender
Genotype CHBV CHCV
ALT p-valuea AST p-valuea Viral load p-valuea M/F p-valuea ALT p-valuea AST p-valuea Viral load p-valuea M/F p-valuea
IRF-1 (410)
AA 0.152 0.268 0.413 0.415 0.488 0.514 0.351 0.548
AG 0.246 0.175 0.411 0.778 0.935 0.798 0.102 0.418
GG 0.788 0.461 0.790 0.783 0.058 0.189 0.017b 0.660
IRF-1 (388)
TT 0.612 0.632 0.570 1.000 0.152 0.268 0.413 0.425
TC 0.220 0.173 0.150 0.663 0.706 0.963 0.855 1.000
CC 0.077 0.261 0.303 1.000 0.571 0.881 0.739 0.499
IFN-g (+874)
AA 0.397 0.382 0.041b 0.773 0.164 0.251 0.403 0.678
AT 0.415 0.465 0.046b 0.398 0.309 0.261 0.586 0.712
TT 0.971 0.777 0.737 0.547 0.487 0.291 0.952 1.000
IFNGR-1 (611)
AA 0.621 0.659 0.847 1.000 0.016b 0.015b 0.033b 0.749
AG 0.340 0.427 0.853 1.000 0.102 0.097 0.418 1.000
GG 0.439 0.537 0.77 1.000 0.211 0.223 0.178 1.000
IFNGR-1 (56)
CC 0.428 0.607 0.759 1.000 0.741 0.327 0.909 1.000
CT 0.424 0.636 0.526 1.000 0.929 0.470 0.621 0.702
TT 0.763 0.794 0.681 1.000 0.844 0.690 0.133 1.000
CHBV, chronic hepatitis B; CHCV, chronic hepatitis C; AST, aspartate aminotransferase; ALT, alanine aminotransferase; M/F, male/female.
a p-Value: calculated using the Pearson Chi-square test; p < 0.05 indicates signiﬁcance. Calculations based on viral load >2000 IU/ml for CHBV19 and >800 000 IU/ml for
CHCV.30
b Signiﬁcant.
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the initial stages of infection.24,25
It has previously been demonstrated that IRF-1 is one of the
key host factors that regulate intracellular HCV replication
through modulation of interferon-stimulated gene-mediated
antiviral responses.26 IRF-1 repression attenuates interferon-
stimulated gene (ISG) responses mediated by the IFN-stimulated
response element (IRF-E, or ISRE). IRF-1 is a pleiotropic
transcription factor, critical for cell defense against viral
infections but also crucial for the development of both the
innate and adaptive responses.26
The identiﬁcation of IRF-1 as a candidate gene marker for both
HBV and HCV progression and severity is supported by consider-
able data demonstrating that IRF-1 plays a key role in host
immunity.27 IRF-1 appears to function as a regulator of cellular
antiviral responses to interferons. Overexpression of IRF-1 has
been shown to induce an antiviral state affecting various viruses,
including vesicular stomatitis virus, encephalomyocarditis virus,
and Newcastle disease virus.25
Analysis of the IFN-g +874 and IFNGR-1 611 genes in the
present cohort revealed an association with HBV infection and
uninfected adults. These ﬁndings are consistent with previous
reports that the IFN-g +874 and a functional –56C/T SNP in the
IFNGR-1 promoter are markers for HBV infection.27 The antiviral
cascade triggered by IFN-g represents a vital event for eradicating
HBV.25 Modulation of IFNGR-1 levels on the cell surface is one
mechanism by which a cell alters its sensitivity to IFN-g, indicating
that IFN-g/IFNGR-1 signaling is of vital importance in the
pathogenesis of CHBV infection.21–28 Conversely, a conﬂicting
study found no signiﬁcant association between IFN-g, IFNGR, and
IRF-1 and HBV infection.23 Differences could be predominantly
attributed to the different population cohorts, patient criteria, and
gene loci analyzed.
Although IFN-g +874 and IFNGR-1 were not associated with
HCV in the present study, the IFN-g 764 position has previously
been linked to HCV treatment response and spontaneous
clearance.29 However it is now known that the interferon lambda
(IFN-l) pathway rather than IFN-g plays a major role in HCV
disease progression and the treatment response.30Several polymorphisms within the IFN-g non-coding regions
and IFNGR-1 have previously been implicated in other autoim-
mune and chronic inﬂammatory conditions.31–33
A number of clinical factors such as viral load, gender, and AST/
ALT levels were correlated with polymorphic genes in order to
genetically determine whether inter-individual differences in the
immune response may also have an impact on outcome. Gender
was not observed as a risk factor for susceptibility to either CHBV
or CHCV.
With regards to CHBV, IFN-g +874 was seen to play a functional
role in relation to viral load, consistent with its known role in the
inhibition and replication of HBV-infected cells.31
IRF-1 410 GG and IFNGR-1 611 AA genotypes were
signiﬁcantly associated with high HCV viral loads, the latter
also correlating to increased AST and ALT levels in CHCV
patients, suggesting a possible role in host susceptibility to HCV
replication and disease progression. Previous studies of IRF-1
promoter polymorphisms in relation to the interferon response
in chronic HCV patients have shown that lower viral loads
correspond to higher IRF-1 promoter activity and to
signiﬁcantly higher proportions of Th1 CD4+ cells after
interferon administration.30
In conclusion, this study suggests that SNPs at various sites of
the IRF-1, IFN-g, and IFNGR-1 genes are associated with the
development of chronic HBV and HCV. These ﬁndings provide
further clues to the pathogenesis of HBV and HCV infection and aid
in elucidating the role of these genes in hepatitis.
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